Sanofi's Rilzabrutinib Gets FDA's Rare-Disease Drug Designation
Sanofi said that its Rilzabrutinib treatment was granted orphan drug designation, which is used in the U.S. by the Food and Drug Administration. The designation is a status assigned to a medicine ...